Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699521 | 0.88 | TSHR (0.36) | GLP1RTSHRTLR2MEN1KMT2A | |
| SCHEMBL13498598 | 0.87 | GLP1R (0.38) | GLP1RTSHRTLR2MEN1KMT2A | |
| SCHEMBL3485752 | 0.87 | GLP1R (0.38) | GLP1RTSHRTLR2MEN1KMT2A | |
| SCHEMBL3485760 | 0.84 | TLR2 (0.38) | GLP1RTSHRTLR2RECQLECE1 | |
| SCHEMBL13936475 | 0.84 | GLP1R (0.41) | GLP1RTSHRTLR2MEN1KMT2A | |
| SCHEMBL13699540 | 0.82 | GLP1R (0.39) | GLP1RTLR2MEN1KMT2AFAAH | |
| SCHEMBL13955335 | 0.80 | GLP1R (0.34) | GLP1RTLR2MEN1KMT2A | |
| SCHEMBL13699632 | 0.79 | GLP1R (0.39) | GLP1RTLR2MEN1KMT2A | |
| SCHEMBL18774076 | 0.78 | MEN1 (0.47) | GLP1RTSHRTLR2MEN1KMT2A | |
| SCHEMBL28978101 | 0.78 | MEN1 (0.47) | GLP1RTSHRTLR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885TSHR 1791/4885TLR2 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.